Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ragnar Löfstedt

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Human & Experimental Toxicology|March 20, 2003
Hormesis and risk communication: a comment to Ortwin RennRagnar Löfstedt
Journal of Hazardous Materials|June 14, 2002
Good and bad examples of siting and building biosafety level 4 laboratories: a study of Winnipeg, Galveston and EtobicokeRagnar Löfstedt
Expert Review of Clinical Pharmacology|January 16, 2014
Tolerability of risk approach and the management of pharmaceutical risksFrederic Bouder, Ragnar Löfstedt
Risk Analysis : an Official Publication of the Society for Risk Analysis|April 27, 2018
Anticipating or Accommodating to Public Concern? Risk Amplification and the Politics of Precaution ReexaminedJamie K Wardman, Ragnar Löfstedt
Public Understanding of Science (Bristol, England)|May 25, 2017
The problems of increasing transparency on uncertaintyMagda Osman, Amanda J Heath, Ragnar Löfstedt
Drug Safety|October 16, 2016
Pharmaceutical Benefit-Risk Communication Tools: A Review of the LiteratureDominic Way, Hortense Blazsin, Ragnar Löfstedt, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|May 2, 2015
Transparency in Europe: A Quantitative StudyFrederic Bouder, Dominic Way, Ragnar Löfstedt, et al.
Trends in Cognitive Sciences|November 1, 2020
Learning from Behavioural Changes That FailMagda Osman, Scott McLachlan, Norman Fenton, et al.
EFSA Journal. European Food Safety Authority|July 7, 2020
Communicating to and engaging with the public in regulatory scienceAnthony Smith, Lucia Parrino, Domagoj Vrbos, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Human & Experimental Toxicology|March 20, 2003
Hormesis and risk communication: a comment to Ortwin RennRagnar Löfstedt
Journal of Hazardous Materials|June 14, 2002
Good and bad examples of siting and building biosafety level 4 laboratories: a study of Winnipeg, Galveston and EtobicokeRagnar Löfstedt
Expert Review of Clinical Pharmacology|January 16, 2014
Tolerability of risk approach and the management of pharmaceutical risksFrederic Bouder, Ragnar Löfstedt
Risk Analysis : an Official Publication of the Society for Risk Analysis|April 27, 2018
Anticipating or Accommodating to Public Concern? Risk Amplification and the Politics of Precaution ReexaminedJamie K Wardman, Ragnar Löfstedt
Public Understanding of Science (Bristol, England)|May 25, 2017
The problems of increasing transparency on uncertaintyMagda Osman, Amanda J Heath, Ragnar Löfstedt
Drug Safety|October 16, 2016
Pharmaceutical Benefit-Risk Communication Tools: A Review of the LiteratureDominic Way, Hortense Blazsin, Ragnar Löfstedt, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|May 2, 2015
Transparency in Europe: A Quantitative StudyFrederic Bouder, Dominic Way, Ragnar Löfstedt, et al.
Trends in Cognitive Sciences|November 1, 2020
Learning from Behavioural Changes That FailMagda Osman, Scott McLachlan, Norman Fenton, et al.
EFSA Journal. European Food Safety Authority|July 7, 2020
Communicating to and engaging with the public in regulatory scienceAnthony Smith, Lucia Parrino, Domagoj Vrbos, et al.
Pageof 1